Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients

Authors

Navina K. Birk, Henry Ford HealthFollow
Saniya Jain, Henry Ford HealthFollow
Louis Massoud, Henry Ford HealthFollow
Diya Ramesh, Henry Ford HealthFollow
Lea Monday, Henry Ford Health
Bruce K. Muma, Henry Ford HealthFollow
Jonathan Williams, Henry Ford HealthFollow
George Alangaden, Henry Ford HealthFollow
Mayur Ramesh, Henry Ford HealthFollow

Recommended Citation

Birk NK, Jain S, Massoud L, Ramesh D, Monday L, Muma B, Williams J, Alangaden G, and Ramesh M. Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients. Open Forum Infect Dis 2022; 9(7):ofac282.

Document Type

Article

Publication Date

7-1-2022

Publication Title

Open Forum Infect Dis

Abstract

We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.

PubMed ID

35859992

Volume

9

Issue

7

First Page

282

Last Page

282